Home > Insider Trading > Filing (0001140361-12-046566)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
810509	Navidea Biopharmaceuticals Inc.	NAVB	In Vitro & In Vivo Diagnostic Substances (2835)	311080091

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1299265	Platinum Partners Value Arbitrage Fund, Lp	152 West 57Th Street 54Th Floor New York NY 10019		No	No	Yes	No
1404598	Platinum-Montaur Life Sciences, Llc	152 W. 57Th Street, 4Th Floor New York NY 10019		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, Par Value $0.001	Disposition	2012-09-04	205,521	$3.80	7,266,847	No	4	S	Direct
Common Stock, Par Value $0.001	Disposition	2012-09-05	64,900	$3.78	7,201,947	No	4	S	Direct
Common Stock, Par Value $0.001	Disposition	2012-09-06	2,200	$3.71	7,199,747	No	4	S	Direct
Common Stock, Par Value $0.001	Disposition	2012-09-07	118,731	$3.61	7,081,016	No	4	S	Direct
Common Stock, Par Value $0.001	Disposition	2012-09-10	20,500	$3.75	7,060,516	No	4	S	Direct
Common Stock, Par Value $0.001	Disposition	2012-09-10	269,919	$3.69	6,790,597	No	4	S	Direct
Common Stock, Par Value $0.001	Disposition	2012-09-19	21,700	$3.22	6,768,897	No	4	S	Direct
Common Stock, Par Value $0.001	Disposition	2012-09-21	4,911	$3.24	6,763,986	No	4	S	Direct
Common Stock, Par Value $0.001	Acquisiton	2012-10-10	37,030	$2.56	6,801,016	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	P	Direct

Footnotes

The reporting persons' sale at a price of $3.80 per share on September 4, 2012 of Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 37,030 shares, with the reporting persons' purchase of shares of Common Stock at a price of $2.56 per share on October 10, 2012 reported herein. The reporting persons have agreed to pay to Navidea Biopharmaceuticals, Inc., $45,472.84, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs.